Jason Gotlib

Hematologist

Medical oncologist, Leukemia specialist

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (2003) CA

Residency: Stanford University School of Medicine (1998) CA

Internship: Stanford University School of Medicine (1996) CA

Medical Education: Stanford University School of Medicine (1995) CA

B.A., Franklin & Marshall College, Biology; HAPOS (1990)

M.D., Stanford, Medicine (1995)

M.S., Stanford, Clinical Epidemiology (2003)

Honors & Awards

NIH K23 Mentored Patient-Oriented Research Career Development Award (#HL04409), National Institutes of Health (2001-2006)

Hematology Division Faculty Teaching Award, Stanford Division of Hematology/Department of Medicine (2005, 2007, 2009)

Charles Dorsey Armstrong Award for Excellence in Patient Care, Stanford Internal Medicine Residency Program (1998)

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
Gotlib, J., Maxson, J. E., George, T. I., & Tyner, J. W. (2013). The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood, 122(10), 1707-1711.

Editorial.
Gotlib, J. (2013). Editorial. Therapeutic advances in hematology, 4(4), 235-236.

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Mesa, R. A., Gotlib, J., Gupta, V., Catalano, J. V., Deininger, M. W., & Verstovsek, S. (2013). Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(10), 1285-1292.

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Gotlib, J., Pardanani, A., Akin, C., Reiter, A., George, T., & Valent, P. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. BLOOD, 121(13), 2393-2401.

Accessory splenules in autoimmune hemolytic anemia
Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. AMERICAN JOURNAL OF HEMATOLOGY, 88(2), 156-156.

ICON: Eosinophil Disorders.
Valent, P., Klion, A. D., Rosenwasser, L. J., Arock, M., Bochner, B. S., & Gleich, G. J. (2012). ICON: Eosinophil Disorders. The World Allergy Organization journal, 5(12), 174-181.

Next-generation sequencing in hematologic malignancies: what will be the dividends?
Merker, J. D., Valouev, A., & Gotlib, J. (2012). Next-generation sequencing in hematologic malignancies: what will be the dividends?. Therapeutic advances in hematology, 3(6), 333-339.

DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups
Ohgami, R. S., Ma, L., Ren, L., Weinberg, O. K., Seetharam, M., & Arber, D. A. (2012). DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. BRITISH JOURNAL OF HAEMATOLOGY, 159(2), 182-190.

World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib, J. (2012). World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. American journal of hematology, 87(9), 903-914.

Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders
Gotlib, J., & Akin, C. (2012). Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders. SEMINARS IN HEMATOLOGY, 49(2), 128-137.

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45-50.

A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.
Zhang, B., Ng, D., Jones, C., Oh, S. T., Nolan, G. P., & Gotlib, J. (2011). A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood, 118(26), 6988-6990.

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2011). Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. HEMATOLOGICAL ONCOLOGY, 29(3), 157-160.

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management
Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 86(8), 678-688.

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. American journal of hematology, 86(8), 677-688.

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., & Tefferi, A. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 789-796.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., & Gotlib, J. (2010). Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. BLOOD, 116(6), 988-992.

Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., & George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600-606.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Oh, S. T., & Gotlib, J. (2010). JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. EXPERT REVIEW OF HEMATOLOGY, 3(3), 323-337.

Eosinophilic myeloid disorders: new classification and novel therapeutic strategies
Gotlib, J. (2010). Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. CURRENT OPINION IN HEMATOLOGY, 17(2), 117-124.

Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update
Tefferi, A., Gotlib, J., & Pardanani, A. (2010). Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. MAYO CLINIC PROCEEDINGS, 85(2), 158-164.

Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
Hidalgo-Curtis, C., Apperley, J. F., Stark, A., Jeng, M., Gotlib, J., & Grand, F. H. (2010). Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 268-273.

Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory
Merker, J. D., Jones, C. D., Oh, S. T., Schrijver, I., Gotlib, J., & Zehnder, J. L. (2010). Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory. JOURNAL OF MOLECULAR DIAGNOSTICS, 12(1), 58-64.

When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings
Pollyea, D. A., George, T. I., Corless, C., & Gotlib, J. (2009). When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 843-846.

On being metachromatic: mystique and misunderstanding in mastocytosis
Gotlib, J. (2009). On being metachromatic: mystique and misunderstanding in mastocytosis. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 779-781.

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
Korver, W., Zhao, X., Singh, S., Pardoux, C., Zhao, J., & Abo, A. (2009). Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. LEUKEMIA, 23(9), 1587-1597.

RNAi screen for rapid therapeutic target identification in leukemia patients
Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., & Druker, B. J. (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(21), 8695-8700.

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., & Felsher, D. W. (2009). Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. NATURE MEDICINE, 15(5), 566-571.

Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation
Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., & Jamieson, C. Hm. (2009). Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(10), 3925-3929.

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., & Arber, D. A. (2009). Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. BLOOD, 113(9), 1906-1908.

A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15-20.

Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission
Medeiros, B. C., Gotlib, J., & Zehnder, J. (2009). Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. LEUKEMIA & LYMPHOMA, 50(5), 851-853.

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
Gotlib, J., & Cools, J. (2008). Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. LEUKEMIA, 22(11), 1999-2010.

Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
Geron, I., Abrahamsson, A. E., Barroga, C. F., Kavalerchik, E., Gotlib, J., & Jamieson, C. Hm. (2008). Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors. CANCER CELL, 13(4), 321-330.

Gene expression and pathway analysis of immune thrombocytopenic purpura
Sood, R., Wong, W., Gotlib, J., Jeng, M., & Zehnder, J. L. (2008). Gene expression and pathway analysis of immune thrombocytopenic purpura. BRITISH JOURNAL OF HAEMATOLOGY, 140(1), 99-103.

Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh, S. T., & Gotlib, J. (2008). Antiangiogenic therapy in myelodysplastic syndromes: is there a role?. Current hematologic malignancy reports, 3(1), 10-18.

Chronic eosinophilic leukemia/hypereosinophilic syndrome.
Gotlib, J. (2008). Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer treatment and research, 142, 69-106.

A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance
Fukumoto, J. S., & Gotlib, J. (2006). A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. AMERICAN JOURNAL OF HEMATOLOGY, 81(11), 870-874.

Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system
Dormady, S. P., Mariappan, M. R., Kao, D., & Gotlib, J. (2006). Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. JOURNAL OF CLINICAL ONCOLOGY, 24(27), 4515-4516.

KIT mutations in mastocytosis and their potential as therapeutic targets
Gotlib, J. (2006). KIT mutations in mastocytosis and their potential as therapeutic targets. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 26(3), 575-?.

Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis
Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., & Zehnder, J. L. (2006). Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. JOURNAL OF MOLECULAR DIAGNOSTICS, 8(3), 330-334.

Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy
Gotlib, J., Cross, N. Cr., & Gilliland, D. G. (2006). Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 19(3), 535-569.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., & Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865-2870.

Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib, J. (2005). Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Current hematology reports, 4(1), 77-84.

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
Gotlib, J. (2005). Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. ACTA HAEMATOLOGICA, 114(1), 7-25.

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. Hm., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., & Weissman, I. L. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. NEW ENGLAND JOURNAL OF MEDICINE, 351(7), 657-667.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 14(4), 307-315.

The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutre, S. E. (2004). The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. BLOOD, 103(8), 2879-2891.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
Coutre, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. SEMINARS IN CANCER BIOLOGY, 14(1), 23-31.

Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib, J., & Greenberg, P. L. (2003). Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 1(4), 473-480.